Key Points
- Omada Health CFO Steven Cook sold 17,950 shares on June 22 at an average price of $18.13, for total proceeds of $325,433.50. After the sale, he still owned 169,259 shares, and the transaction reduced his stake by 9.59%.
- Omada Health recently posted a narrower-than-expected loss, reporting EPS of -$0.05 versus analysts’ expectations of -$0.08, on revenue of $78.05 million for the quarter. Analysts currently expect the company to post -0.01 EPS for the full year.
- Wall Street sentiment remains mostly positive, with 10 analysts rating the stock a Buy, two Hold, and one Sell. The consensus price target is $22.91, though some firms have trimmed their targets recently.
Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CAO Craig Gracey sold 2,083 shares of the firm's stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $18.00, for a total transaction of $37,494.00. Following the completion of the sale, the chief accounting officer owned 7,108 shares in the company, valued at $127,944. This represents a 22.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Craig Gracey also recently made the following trade(s):
- On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The stock was sold at an average price of $17.42, for a total value of $120,093.48.
Omada Health Trading Up 1.5%
Shares of OMDA stock opened at $18.58 on Thursday. The business's 50-day moving average price is $16.22 and its 200-day moving average price is $14.79. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92. The firm has a market capitalization of $1.10 billion and a price-to-earnings ratio of -68.81.
Omada Health (NASDAQ:OMDA - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The firm had revenue of $78.05 million for the quarter. On average, sell-side analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new position in Omada Health during the second quarter worth about $44,402,000. Millennium Management LLC grew its position in Omada Health by 1,195.0% during the fourth quarter. Millennium Management LLC now owns 2,272,168 shares of the company's stock valued at $35,855,000 after acquiring an additional 2,096,705 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Omada Health by 23.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,855,721 shares of the company's stock valued at $29,283,000 after purchasing an additional 346,588 shares during the last quarter. Divisadero Street Capital Management LP bought a new position in shares of Omada Health during the third quarter valued at about $30,510,000. Finally, Jefferies Financial Group Inc. bought a new position in Omada Health during the 4th quarter worth approximately $16,948,000.
Wall Street Analysts Forecast Growth
OMDA has been the topic of a number of research analyst reports. Citigroup reaffirmed an "outperform" rating on shares of Omada Health in a research report on Friday, May 8th. Morgan Stanley reissued an "overweight" rating and issued a $30.00 price target on shares of Omada Health in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price target on shares of Omada Health in a research note on Friday, May 8th. Barclays lifted their price objective on shares of Omada Health from $18.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, May 8th. Finally, BMO Capital Markets reduced their target price on Omada Health from $27.00 to $18.00 and set an "outperform" rating for the company in a report on Friday, March 6th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $22.91.
Check Out Our Latest Stock Analysis on Omada Health
Omada Health Company Profile
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
